- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 624632, 15 pages
Comparison of Prostate-Specific Promoters and the Use of PSP-Driven Virotherapy for Prostate Cancer
1Department of Pathology and Laboratory Medicine,
The University of Tennessee Health Science Center, Cancer Research Building, Room 218, 19 South Manassas Street, Memphis, TN 38163, USA
2Department of Urology, University of Tennessee Health Science Center, Memphis, TN 38163, USA
Received 12 October 2012; Accepted 19 December 2012
Academic Editor: Changqing Su
Copyright © 2013 Yi Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. Rodriguez, E. R. Schuur, H. Y. Lim, G. A. Henderson, J. W. Simons, and D. R. Henderson, “Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells,” Cancer Research, vol. 57, no. 13, pp. 2559–2563, 1997.
- D. C. Yu, G. T. Sakamoto, and D. R. Henderson, “Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy,” Cancer Research, vol. 59, no. 7, pp. 1498–1504, 1999.
- D. C. Yu, Y. Chen, M. Seng, J. Dilley, and D. R. Henderson, “The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts,” Cancer Research, vol. 59, no. 17, pp. 4200–4203, 1999.
- W. J. Muller, F. S. Lee, C. Dickson, G. Peters, P. Pattengale, and P. Leder, “The int-2 gene product acts as an epithelial growth factor in transgenic mice,” The EMBO Journal, vol. 9, no. 3, pp. 907–913, 1990.
- J. E. Oesterling, “Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate,” Journal of Urology, vol. 145, no. 5, pp. 907–923, 1991.
- C. D. Jurincic, H. U. Pixberg, A. Casser, and K. F. Klippel, “Prostate-specific antigen in prostatic carcinoma,” Urologia Internationalis, vol. 45, no. 3, pp. 153–159, 1990.
- F. C. Hamdy, J. Lawry, J. B. Anderson, M. A. Parsons, R. C. Rees, and J. L. Williams, “Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer,” British Journal of Urology, vol. 69, no. 4, pp. 392–396, 1992.
- S. Pang, S. Taneja, K. Dardashti et al., “Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer,” Human Gene Therapy, vol. 6, no. 11, pp. 1417–1426, 1995.
- Y. Matuo, P. S. Adams, N. Nishi et al., “The androgen-dependent rat prostate protein, probasin, is a heparin-binding protein that co-purifies with heparin-binding growth factor-1,” In Vitro Cellular and Developmental Biology, vol. 25, no. 6, pp. 581–584, 1989.
- J. G. Dodd, P. C. Sheppard, and R. J. Matusik, “Characterization and cloning of rat dorsal prostate mRNAs. Androgen regulation of two closely related abundant mRNAs,” The Journal of Biological Chemistry, vol. 258, no. 17, pp. 10731–10737, 1983.
- N. M. Greenberg, F. J. Demayo, P. C. Sheppard et al., “The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice,” Molecular Endocrinology, vol. 8, no. 2, pp. 230–239, 1994.
- N. M. Greenberg, F. Demayo, M. J. Finegold et al., “Prostate cancer in a transgenic mouse,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 8, pp. 3439–3443, 1995.
- S. A. Halter, P. Dempsey, Y. Matsui et al., “Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-α: characterization of mammary gland and skin proliferations,” The American Journal of Pathology, vol. 140, no. 5, pp. 1131–1146, 1992.
- Y. Matsui, S. A. Halter, J. T. Holt, B. L. M. Hogan, and R. J. Coffey, “Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice,” Cell, vol. 61, no. 6, pp. 1147–1155, 1990.
- R. F. Tutrone, R. A. Ball, D. M. Ornitz, P. Leder, and J. P. Richie, “Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model,” Journal of Urology, vol. 149, no. 3, pp. 633–639, 1993.
- M. S. Steiner, C. T. Anthony, Y. Lu, and J. T. Holt, “Antisense c-myc retroviral vector suppresses established human prostate cancer,” Human Gene Therapy, vol. 9, no. 5, pp. 747–755, 1998.
- D. F. Pierce, M. D. Johnson, Y. Matsui et al., “Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1,” Genes and Development, vol. 7, no. 12, pp. 2308–2317, 1993.
- D. F. Pierce Jr., A. E. Gorska, A. Chytil et al., “Mammary tumor suppression by transforming growth factor β1 transgene expression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 10, pp. 4254–4258, 1995.
- M. S. Steiner, C. Anthony, and M. Paul, “Transforming growth factor β1 overexpression inhibits seminal vesicle development in transgenic mice,” Journal of Urology, vol. 155, p. 350, 1996.
- A. Fire, S. White Harrison, and D. Dixon, “A modular set of lacZ fusion vectors for studying gene expression in Caenorhabditis elegans,” Gene, vol. 93, no. 2, pp. 189–198, 1990.
- Y. Lu, Y. Zhang, and M. S. Steiner, “Efficient identification of recombinant adenoviruses by direct plaque-screening,” DNA and Cell Biology, vol. 17, no. 7, pp. 643–645, 1998.
- Y. Lu, J. Carraher, Y. Zhang et al., “Delivery of adenoviral vectors to the prostate for gene therapy,” Cancer Gene Therapy, vol. 6, no. 1, pp. 64–72, 1999.
- F. L. Graham and L. Prevec, “Manipulation of adenovirus vectors,” in Methods in Molecular Biology, E. J. Murray, Ed., vol. 7 of Gene Transfer and Expression Protocols, pp. 109–128, Humana Press, Clifton, NJ, USA, 1991.
- J. F. Karr, J. A. Kantor, P. H. Hand, D. L. Eggensperger, and J. Schlom, “The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line,” Cancer Research, vol. 55, no. 11, pp. 2455–2462, 1995.
- T. M. T. Mulders, P. F. Bruning, and J. M. G. Bonfrer, “Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker,” European Journal of Surgical Oncology, vol. 16, no. 1, pp. 37–41, 1990.
- J. A. Eastham, S. H. Chen, I. Sehgal et al., “Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models,” Human Gene Therapy, vol. 7, no. 4, pp. 515–523, 1996.
- K. L. Berkner, “Development of adenovirus vectors for the expression of heterologous genes,” BioTechniques, vol. 6, no. 7, pp. 616–629, 1988.
- W. C. Russell, “Update on adenovirus and its vectors,” Journal of General Virology, vol. 81, no. 11, pp. 2573–2604, 2000.
- M. S. Steiner, X. Zhang, Y. Wang, and Y. Lu, “Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde,” Cancer Research, vol. 60, no. 16, pp. 4419–4425, 2000.
- M. S. Steiner, Y. Zhang, F. Farooq, J. Lerner, Y. Wang, and Y. Lu, “Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence,” Cancer Gene Therapy, vol. 7, no. 3, pp. 360–372, 2000.
- D. L. Paielli, M. S. Wing, K. R. Rogulski et al., “Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse,” Molecular Therapy, vol. 1, no. 3, pp. 263–274, 2000.
- S. O. Freytag, K. R. Rogulski, D. L. Paielli, J. D. Gilbert, and J. H. O. Kim, “A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy,” Human Gene Therapy, vol. 9, no. 9, pp. 1323–1333, 1998.
- N. Pariente, K. Morizono, M. S. Virk et al., “A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration,” Molecular Therapy, vol. 15, no. 11, pp. 1973–1981, 2007.
- Y. Hu, D. Stout, and L. Wu, “A dual-targeted lentiviral vector homing in on prostate bone metastases,” Molecular Therapy, vol. 15, no. 11, pp. 1906–1908, 2007.
- W. J. Van Houdt, Y. S. Haviv, B. Lu et al., “The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma,” Journal of Neurosurgery, vol. 104, no. 4, pp. 583–592, 2006.
- M. Krajewska, S. Krajewski, S. Banares et al., “Elevated expression of inhibitor of apoptosis proteins in prostate cancer,” Clinical Cancer Research, vol. 9, no. 13, pp. 4914–4925, 2003.
- I. V. Ulasov, Z. B. Zhu, M. A. Tyler et al., “Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma,” Human Gene Therapy, vol. 18, no. 7, pp. 589–602, 2007.
- I. V. Ulasov, A. A. Rivera, A. M. Sonabend et al., “Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy,” Cancer Biology and Therapy, vol. 6, no. 5, pp. 679–685, 2007.
- Y. Li, Y. Chen, J. Dilley et al., “Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy,” Molecular Cancer Therapeutics, vol. 2, no. 10, pp. 1003–1009, 2003.
- A. E. Bilsland, A. Merron, G. Vassaux, and W. N. Keith, “Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses,” Cancer Research, vol. 67, no. 3, pp. 1299–1307, 2007.
- M. Takakura, M. Nakamura, S. Kyo et al., “Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination,” Cancer Gene Therapy, vol. 17, no. 1, pp. 11–19, 2010.
- T. G. Huang, M. J. Savontaus, K. Shinozaki, B. V. Sauter, and S. L. C. Woo, “Telomerase-dependent oncolytic adenovirus for cancer treatment,” Gene Therapy, vol. 10, no. 15, pp. 1241–1247, 2003.
- M. Kuppuswamy, J. F. Spencer, K. Doronin, A. E. Tollefson, W. S. M. Wold, and K. Toth, “Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression,” Gene Therapy, vol. 12, no. 22, pp. 1608–1617, 2005.
- M. Boyd, R. J. Mairs, W. N. Keith et al., “An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects,” Journal of Gene Medicine, vol. 6, no. 8, pp. 937–947, 2004.
- T. Fukazawa, J. Matsuoka, Y. Naomoto, Y. Maeda, M. L. Durbin, and N. Tanaka, “Malignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapy,” Cancer Research, vol. 68, no. 17, pp. 7120–7129, 2008.
- M. A. Trujillo, M. J. Oneal, J. Davydova, E. Bergert, M. Yamamoto, and J. C. Morris, “Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer,” Breast Cancer Research, vol. 11, no. 4, article R53, 2009.
- X. Li, C. Jung, Y. H. Liu et al., “Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis,” Journal of Gene Medicine, vol. 8, no. 6, pp. 679–689, 2006.
- H. Nakaya, A. Ishizu, H. Ikeda et al., “In vitro model of suicide gene therapy for alpha-fetoprotein-producing gastric cancer,” Anticancer Research, vol. 23, no. 5, pp. 3795–3800, 2003.
- Y. Adachi, P. N. Reynolds, M. Yamamoto et al., “A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging,” Cancer Research, vol. 61, no. 21, pp. 7882–7888, 2001.
- H. A. Ono, J. G. Davydova, Y. Adachi et al., “Promoter-controlled infectivity-enhanced conditionally replicative adenoviral vectors for the treatment of gastric cancer,” Journal of Gastroenterology, vol. 40, no. 1, pp. 31–42, 2005.
- M. Yamamoto, J. Davydova, M. Wang et al., “Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer,” Gastroenterology, vol. 125, no. 4, pp. 1203–1218, 2003.